Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3

Agnes Leffler, Ingela Ahlstedt, Susanna Engberg, Arne Svensson, Martin Billger, Lisa Öberg, Magnus Bjursell, Erik Lindström, Bengt von Mentzer

► To cite this version:

Agnes Leffler, Ingela Ahlstedt, Susanna Engberg, Arne Svensson, Martin Billger, et al.. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. *Biochemical Pharmacology*, 2009, 77 (9), pp.1522. 10.1016/j.bcp.2009.01.020 . hal-00493489

HAL Id: hal-00493489

<https://hal.science/hal-00493489>

Submitted on 19 Jun 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3

Authors: Agnes Leffler, Ingela Ahlstedt, Susanna Engberg, Arne Svensson, Martin Billger, Lisa Öberg, Magnus Bjursell, Erik Lindström, Bengt von Mentzer

PII: S0006-2952(09)00055-0
DOI: doi:10.1016/j.bcp.2009.01.020
Reference: BCP 10080

To appear in: *BCP*

Received date: 19-11-2008
Revised date: 27-1-2009
Accepted date: 30-1-2009

Please cite this article as: Leffler A, Ahlstedt I, Engberg S, Svensson A, Billger M, Öberg L, Bjursell M, Lindström E, von Mentzer B, Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3, *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2009.01.020

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Short title: NK receptor pharmacology

Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3.

Agnes Leffler^a, Ingela Ahlstedt^a, Susanna Engberg^a, Arne Svensson^a, Martin Billger^b,

Lisa Öberg^a, Magnus Bjursell¹, Erik Lindström² and Bengt von Mentzer^{}.*

AstraZeneca R&D, Mölndal, Sweden.

*Corresponding author: Dr. Bengt von Mentzer, Pharmnovo AB, Medicinaregatan 8A, S-413 46 Göteborg, Sweden. Tel.: +46 31 7411816, Fax. +46 31 7411701, E-mail: bengt.mentzer@pharmnovo.com

¹Current affiliation: Royal Institute of technology, Albanova University Centre, SE-10691 Stockholm, Sweden

²Current affiliation: Medivir AB, PO Box 1086, S-141 22, Huddinge, Sweden

^aDepartment of Bioscience

^bSafety Assessment

Key words: Aprepitant; Saredutant; Talnetant; NK receptors; Species difference; NK-receptor function; Chemistry; NK-receptor sequences

Abbreviations: NKR, tachykinin NK receptor; SP, Substance P; NKA, Neurokinin A; NKB, Neurokinin B; AA, amino acids; FLIPR, Fluorometric Imaging Plate Reader; TM. trans membrane

Abstract

Tachykinin NK receptors (NKR) differ to a large degree among species with respect to their affinities for small molecule antagonists. The aims of the present study were to clone NKRs from gerbil (NK₂R and NK₃R) and dog (NK₁R, NK₂R, NK₃R) in which the sequence was previously unknown and to investigate the potency of several NKR antagonists at all known human, dog, gerbil and rat NKRs.

The NKR protein coding sequences were cloned and expressed in CHO cells. The inhibitory concentrations of selective and non-selective NKR antagonists were determined by inhibition of agonist-induced mobilization of intracellular Ca²⁺. Receptor homology models were constructed based on the rhodopsin crystal structure to investigate and identify the antagonist binding sites and interaction points in the trans membrane (TM) regions of the NKRs.

Data collected using the cloned dog NK₁R confirmed that the dog NK₁R displays similar pharmacology as the human and the gerbil NK₁R, but differs greatly from the mouse and the rat NK₁R. Despite species-related AA differences located close to the antagonist binding pocket of the NK₂R, they did not affect the potency of the antagonists ZD6021 and saredutant. Two AA differences located close to the antagonist binding site of NK₃R likely influence the NK₃R antagonist potency, explaining the 3-10-fold decrease in potency observed for the rat NK₃R. For the first time, detailed pharmacological experiments in vitro with cloned NKRs demonstrate that not only human, but also dog and gerbil NKR displays similar antagonist pharmacology while rat diverges significantly with respect to NK₁R and NK₃R.

1. Introduction

Several small molecule antagonists selective for tachykinin NK₁R, NK₂R and NK₃R are in clinical development and the selective NK₁R antagonist aprepitant is approved for treatment of emesis in response to cytostatic treatment in cancer patients [1]. During the development of selective NK₁R antagonists, Beresford *et al.* discovered large discrepancies in the affinity for NK₁R from different species [2]. This led to the NK₁R family being grouped into two sub-families based on the orthologous receptor's affinity to small molecule antagonists. The first sub-family consists of the human, guinea pig, rabbit, dog, gerbil and ferret NK₁R, and the second sub-family of the rat and mouse homologues [2,3,4,5]. Thus, several disease-related animal models in species other than rat or mouse have been developed for evaluation of NK₁R antagonists [6,7,8,9,10]. Amino acid residues in the NK₁R responsible for species-dependent differences in antagonist pharmacology have been studied in detail, especially human Glu97, Val116 and Ser290 [5,11,12,13,14]. However, although the dog appears to be an appropriate species in detecting anti-emetic effects with selective NK₁R antagonists intended for clinical use [15], the pharmacology of the dog NK₁R at the molecular level, and its homology to the human NK₁R, remain unknown to our knowledge.

Consistent species-related differences in the pharmacology of NK₂R have not been reported either, although recent publications demonstrated that the selective NK₂R antagonist MEN15596 and analogues MEN14268 and MEN13918 had a marked species selectivity for inhibiting NK₂R-mediated effects in human, guinea pig and pig urinary bladder, while being 1,000-fold less potent at the rat and mouse NK₂R expressed in urinary bladder [16,17]. By contrast, species-dependent differences were

not observed with MEN11420 (nepadutant) [18] or saredutant [19] Detailed site-directed mutagenesis studies suggested that the Ile202 residue, located in the upper part of TM5 in the human NK₂R was, at least in part, responsible for these differences [16] Still, the homology between the human NK₂R and that of species commonly used in tachykinin receptor pharmacology studies, such as dog and gerbil, has not been reported.

Furthermore, species-related differences in functional response profiles between human and mouse/rat have been reported for selective tachykinin NK₃R antagonists. Compounds from different structural classes have 5-10-fold lower potency and 10-50-fold lower affinity for rodent NK₃R compared to human counterparts [20,21] Site-directed mutagenesis studies indicate that two amino acids in the second trans membrane domain of the human NK₃R (Met134 and Ala146) were responsible for these species differences [20,22] However, as is the case for NK₂R, the identity of NK₃R from dog and gerbil remain unknown.

Thus, there are clearly gaps in our knowledge with respect to which species most likely will predict clinical efficacy and selectivity for NK₁R, NK₂R or NK₃R antagonists. Furthermore, the lack of antagonist affinity data will complicate species selection for toxicological studies intended to detect adverse effects upon blocking of receptor signalling. In the current study, we have cloned and sequenced the dog NK₁R, NK₂R and NK₃R and the gerbil NK₂R. This should increase the understanding of the molecular mechanisms underlying the species related differences in NKR pharmacology, which would facilitate more relevant model system selection.

2. Material and Methods

2.1. Chemicals

Substance P, neurokinin A and Pro7neurokinin B were purchased from Bachem (Peninsula Laboratories Inc, San Carlos, CA). ZD6021 was synthesized at AstraZeneca, Wilmington, USA [23]. Aprepitant [24], RP67580 [25], CP-99,994 [26], saredutant [19], talnetant [27,28] and osanetant [29,30] were synthesized at AstraZeneca Mölndal, Sweden.

2.2. Molecular cloning of the gerbil and dog NK receptors

The sequences for the human and rat NKR subtypes and the gerbil NK₁R have been published previously (see Table 1 for accession numbers, [5]. The receptor sequences for the gerbil NK₂R and the dog NK₁R, NK₂R and NK₃R were largely unknown and are presented in this paper and submitted to the EMBL GenBank database under the accession numbers listed in Table 2. The gerbil NK₃R sequence has been cloned and was presented in a recent study [31].

Dog hypothalamus was used as a source for cloning NK₁R and NK₃R. Dog ileum and gerbil colon were used as sources for cloning of the respective NK₂R. Total RNA was prepared from the different tissues with RNA-STAT-60 (Tel-Test Inc, Friendswood, Texas, USA). One µg of total RNA from each tissue sample was used for the first strand cDNA synthesis using SMART RACE cDNA Amplification kit (BD Biosciences, Mountain View, CA, USA). ClustalW alignment of NK₁R, NK₂R and NK₃R sequences from human, rat, mouse and guinea pig was used to select primers with high homology between different species. Primers used in the 3'RACE and in

the 5'RACE are listed in Table 2. The RACE fragments were characterized and cloned fragments containing gerbil and dog specific NK₁R, NK₂R and NK₃R sequences spanning the open reading frame were identified. Complementary DNA (2.5 µl) from the harvested tissues indicated above was used in the optimized full-length PCR with forward and reverse primers (20 µM of each), 1xPCR buffer, 5 mM of each dNTP and 1 U Pfu Ultra (Stratagene, La Jolla, CA, USA). A Kozak sequence (GCCACC) was introduced before the ATG in each construct. Conditions were optimized for each primer pair used. The resulting PCR products for the gerbil and dog NK₁R and NK₂R were cloned into pIRESHyg2 expression vector (Clontech, Palo Alto, CA, USA). The full-length cDNA of dog and gerbil NK₃ receptor was cloned into pCDNA/FRT expression vector (Invitrogen, Carlsbad, CA, USA). In order to construct a full length clone of dog NK₃R, the 5'-end of the dog NK₃R was cloned using genomic sequence data (TI number 356163905) from a trace file as a template for PCR reactions. Multiple sequence alignments were constructed using ClustalX version 2.0 [32], and the TM domains were predicted using the TMHMM server version 2.0 (<http://www.cbs.dtu.dk/services/TMHMM/>). A position in the alignments is considered TM if the majority of the individual sequences are predicted to be TM at that position.

2.3. Cell culture and transfection

Chinese Hamster Ovary (CHO) cells (ATCC, Middlesex, UK) or CHO-FlpIN cells (Invitrogen, Carlsbad, CA, USA) were transfected with the different constructs. All accession numbers for the sequences used to transfect the CHO cells are listed in table

2. NK₁₋₃ R-containing clones were selected by growth in appropriate selection media and tested for functionality in a Ca²⁺ mobilization assay.

CHO cells stably expressing human NK₁R was supplied by AstraZeneca R&D, Wilmington, USA and human NK₂R, rat NK₁R, rat NK₂R and rat NK₃R were transfected in house (see Table 1 for gene accession numbers). Stable transfectants were maintained by supplementing culture media (NutMix F12 (HAM) with Glutamax I and 10% FBS) (Invitrogen, Carlsbad, CA, USA) with suitable selection depending on the expressing vector. Cultures were kept at 37°C in a 5% CO₂-incubator and routinely passaged when 70-80% confluent for up to 20-25 passages.

2.4. Calcium mobilization assay

Ca²⁺ mobilization was studied in CHO cells or in CHO FlpIn cells stably expressing human, rat, gerbil or dog NK1-3 receptors using the cytoplasmic Ca_i²⁺ indicator Fluo-4 (TEFLABS 0152, Austin, TX, USA). Cells were seeded into black-walled clear-base 96-well plates (Costar, #3904) at a density of 35,000 cells per well in culture media and grown for 24 h in a 37°C CO₂-incubator. The cells were incubated with 4 µM of Fluo-4 (TEFLABS 0152) in loading media (Nut Mix F12 (HAM), glutamax I, 22 mM HEPES, 2.5 mM probenecid (P-8761, Sigma, St. Louis, MO, USA) and 0.04 % pluronic F-127 (P-2443 Sigma, St. Louis., MO, USA) for 30 minutes in a 37°C CO₂-incubator. The Fluo-4-loaded cells were then washed three times in assay buffer (Hanks Balanced Salt Solution, 20 mM HEPES, 2.5 mM probenecid and 0.1% BSA). The plates were placed into the Fluorometric Imaging Plate Reader (FLIPR™) to monitor cell fluorescence (λ_{ex} = 488nm, λ_{em} = 540nm) before and after the addition of antagonists and/or agonists. Antagonists and agonists were dissolved in assay buffer (final DMSO, D2650, Sigma. concentration kept below 1%) in 96-well plates

and added to the loaded cells by the automated pipettor in the FLIPR™. Loaded cells were pre-incubated with antagonists for 2 minutes before addition of agonist (0.08 nM SP for NK₁R, 0.15 nM NKA for NK₂R and 1.0 nM pro7NKB for NK₃R). Ca_i²⁺ responses were measured as peak fluorescence intensity minus basal fluorescence after agonist addition.

2.6. Rhodopsin homology model

The sequences of the human NK₁₋₃R were aligned to the bovine rhodopsin and a subset of rhodopsin sequences, covering different degrees of sequence identity. The pair wise alignments of NK₁₋₃R and rhodopsin, were extracted and adjusted manually to optimize compatibility with structure and frequently occurring sequence motifs amongst GPCRs. The rhodopsin-NK₁₋₃R alignment was used as input for the automatic modeling and used for the evaluation of the WhatCheck module [33]. All binding site results and discussions are based on predictions drawn from NK₁₋₃R modified rhodopsin homology model. A limitation of the Whatif modeling tool is that insertions and gaps are not considered. In this case, however, the active site should not be affected by this limitation.

2.7. Data analysis

The calcium mobilization data generated *in vitro* were fitted to a four parameter equation using Excel Fit. IC₅₀s for antagonists were determined from concentration-response curves for each compound. Potency (K_B)-values for antagonists were calculated using the Cheng-Prusoff equation [34] and expressed as pK_B-values (pK_B = -log K_B). All data are expressed as Mean ± S.E.M.

3. Results

3.1. Sequence characterization and antagonist pharmacology of the tachykinin NK₁ receptor

Multiple sequence alignments of the gerbil, human, dog, rat, mouse and guinea pig NK₁R are shown in Fig. 1A. Unlike rat and gerbil, the dog NK₁R displays 100% homology with human in the trans-membrane regions. Thus, the Val116 and Ile290 residues, previously identified as important for antagonist binding, are identical between the dog and the human NK₁ receptor sequences. Also extracellular residues such as Glu97 have also been suggested as being responsible for species selectivity of antagonists. Indeed, gerbil and dog NK₁R also contained a Glu residue in this position while rat and mouse counterparts contained Val97.

The selective NK₁R antagonists aprepitant (Fig. 1B, Table 3), CP99,994 (Table 3), and the pan-NK antagonist ZD6021 (Table 3) were slightly more potent (5-10 fold) inhibitors of the SP-induced responses in cells expressing the dog compared to the human NK₁R. RP67580 displayed similar potency at NK₁R from all species evaluated (Table 3).

Fig 1C illustrates a rhodopsin-NK₁R homology model which emphasizes the role of AA 116 and 290 in dictating species differences in NK₁R antagonist pharmacology. The polar 290Ser in rat is smaller and less hydrophobic compared to the non-polar 290Ile present in human and dog NK₁R. In contrast, the Leu116Val (rat/human) is a rather conservative AA exchange. There are no other species-related differences in any of the other residues found to be close to the aprepitant binding site using this model (Fig 1C).

3.2. Sequence characterization and antagonist pharmacology at the tachykinin NK₂ receptor

The alignments of the gerbil, human, dog, rat, mouse and guinea pig NK₂Rs, are shown in Fig. 2A. The residues located in the proposed saredutant binding site differ between species. Position 202 located within TM 5 is an Ile in the human and dog NK₂R while the gerbil and rat NK₂R have a Phe in this position. Position 205, also located in TM 5, is Ile in human, rat and dog NK₂R and Val in gerbil NK₂R, while position 267 (located in TM6) has Leu in the human, rat and gerbil NK₂R, which is replaced by a Phe in the dog NK₂R.

Despite the interspecies differences in AA in TM regions, the selective NK₂R antagonist saredutant (Fig. 2B, Table 3), and the pan-NKR antagonist ZD6021 (Table 3), had a similar potency at the NK₂R from the various species.

Fig. 2C illustrates the chemical structures of AA that differ between species and that are presumed to be involved in NK₂R binding of saredutant. All the differences between AA in the NK₂R binding site contain neutral, nonpolar AA. Even though there are differences in the hydrophobicity among residues, they do not seem to affect the potency of the tested NK₂R antagonists (Table 3).

3.3. Sequence characterization and antagonist pharmacology at the tachykinin NK₃ receptor

Alignments of the gerbil, human, dog, rat, mouse and guinea pig NK₃R sequences are shown in Fig. 3A. Key residues important for the binding of talnetant (Met134, Ala146 and Ile317) are identical between gerbil, dog and human, while the corresponding residues in the rat and mouse sequences are Val134, Gly146 and Val317 respectively.

The selective NK₃R antagonists talnetant (Fig. 3B and Table 3) and osanetant (Table 3) had similar potency at human, dog and gerbil NK₃R while being approximately 10-fold less potent for the rat NK₃R. Furthermore, the pan-NKR antagonist ZD6021 also displayed 10-fold higher potency at human, dog and gerbil NK₃R compared to rat NK₃R (Table 3).

Fig. 3C illustrates the rhodopsin NK₃R homology model which emphasizes the role of key residues for talnetant binding. The human NK₃R positions 265 and 306 differ from all other species studied. The dog NK₃R has a Met at position 202 while the other species have an Ile. Nevertheless, based on the pharmacological profile of antagonists at NK₃R for the various species it appears as if the rat/mouse-specific AA at residues 134, 146 and 317 may play a role in the lower potency of NK₃R antagonists at rat NK₃R.

4. Discussion

It has been known for quite some time that there are major differences in the affinity of many selective NK₁R antagonists between human and rat/mouse NK₁R. Therefore, since these commonly used experimental animals are not always suitable for evaluation of clinically relevant compounds, other species have been used instead, including gerbils and dogs. Indeed, gerbils have been used for detecting potential behavioural [6] anti-depressive [9], visceral anti-hyper algesic [10] and gut motility [7] effects of NK₁R antagonists. We recently showed that the gerbil NK₁R shares key residues (Glu97, Val116, Ile290) with the human NK₁R homologue and that it has similar affinity for several known NK₁R antagonists [5] (Fig 1C). Dogs are often used to study the efficacy of anti-emetic compounds like NK₁R antagonists [15]. The current study extends our previous findings in that the dog NK₁R also contains the

1 same important residues for antagonist function as human and gerbil NK₁R. This
2 provides confirmation at the molecular level that the dog belongs to the human-like
3 NK₁R sub-family which has been previously suggested based on experiments *in vivo*
4 [35]. Interestingly, the compounds ZD6021, CP99,994 and aprepitant were actually
5 slightly more potent (5-10-fold) at dog NK₁R compared to gerbil and man. The reason
6 for this is unclear since the receptors display 100% homology in the TM region.
7 RP67580, often referred to as a rat-selective NK₁R antagonist, was equipotent at dog,
8 rat and man. Hence, the rat-selectivity is not supported in the current study and is in-
9 line with previous data [5]. Aprepitant is clearly less potent at rat NK₁R than at NK₁R
10 from other species. However, based on our data, aprepitant could be useful as a tool
11 compound in rat models since it displays similar potency as RP67580, an NK₁R
12 antagonist commonly used in rat models, but appears to have better DMPK properties
13 such as CNS penetration and metabolic half-life [36].

14 Cloning and sequencing of gerbil and dog NK₂R provides data for a more thorough
15 comparison between species. In contrast to NK₁R, rather large discrepancies were
16 found in the TM region in the NK₂R. Residues 202, 205 and 267 had a variety of
17 amino acids in this position among species (Fig 2C). Interestingly, all three of these
18 residues have been implicated in the binding of NK₂R antagonists [37]. Despite the
19 potential importance of these residues for binding and the rather large degree of
20 variation between species, we were unable to identify significant differences of the
21 potency of saredutant and ZD6021 at NK₂R among the species studied. However, it
22 can not be excluded that the potency of structurally different compounds could have
23 different potency at NK₂R from gerbil and dog [16].

24 Consistent with previous findings by [38], both talnetant and osanetant displayed
25 about a 5-10-fold lower potency at the rat NK₃R compared to the human NK₃R.

1 ZD6021 also displayed a relatively weak potency for rat NK₃R (30-fold weaker than
2 at human NK₃R). The current study extends these findings demonstrating that the
3 antagonists tested have similar potency at dog and gerbil NK₃R as to human NK₃R.
4 Recent data show that talnetant and osanetant interact within overlapping but not
5 identical binding pockets in the human tachykinin NK₃R trans membrane domains
6 [39]. The human-like pharmacology of gerbil and dog NK₃R is consistent with the
7 presence of a methionine located in position 134, a residue that has previously been
8 shown to be importance for talnetant and osanetant binding to the human NK₃R (Fig
9 3C). The Ile317Val AA change may induce less sterical hindrance, and may affect the
10 functional potency of the tested compounds (Fig 3C). The above suggestions support
11 that gerbils and dog represent appropriate species for evaluating the efficacy of
12 tachykinin NK₃R antagonists intended for clinical use. Indeed, osanetant has
13 demonstrated anxiolytic-like and antidepressant-like effects in gerbils [40].
14 Single nucleotide polymorphisms in genes encoding receptors can affect many aspects
15 of receptor function and antagonist binding. For instance, four variants of the human
16 NK₂R are common within the human population [41]. The current study utilized the
17 Thr23_Arg375 variant, however saredutant and ZD6021 display similar potency at all
18 four human variants. If AA-exchanging polymorphisms in NKRs occur within or
19 between strains of the experimental animals compared here is unknown to our
20 knowledge.
21 Given the above species difference in NKR pharmacology the study of receptor-
22 mediated toxicology of any NKR modulator, both agonist and antagonists, is not
23 trivial. Ideally, for such studies to be meaningful, selected species for toxicology
24 testing should express the receptor in a similar way and have similar functions as in
25 humans. Concomitantly, selected species should be well characterized with historical

data, in order to differentiate any treatment related lesions from spontaneous
(background) pathology. For these reasons, studies of potential toxicology of NK₂R
antagonists seem to be appropriately conducted in well-known species such as the rat
and dog, while dogs appear to suffice for detected potential unwanted effects of NK₁R
and NK₃R antagonism.

References

- [1] Quartara L, Altamura M. Tachykinin receptors antagonists: from research to clinic. *Curr Drug Targets* 2006;7:975-92.
- [2] Beresford IJM, Birch PJ, Hagan RM, Ireland SJ. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. *Br J Pharmacol* 1991;104:292-93.
- [3] Apell KC, Fragale BJ, Loscig J, DSingh S, Tomchuk BE. Antagonists that demonstrate species difference in neurokinin-1 receptor. *Mol Pharmacol* 1992;41(4):772-8.
- [4] Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. *Eur J Pharmacol* 1999;375:51–60.
- [5] Engberg S, Ahlstedt A, Leffler A, Lindström E, Kristensson E, Svensson A, Pålman I, Johansson A, Drmota T, von Mentzer B. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors. *Biochem Pharmacol* 2007;73:259-69.
- [6] Bristow LJ, Young L. Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils. *Eur J Pharmacol* 1994;253:245-52.
- [7] Okano S, Ikeura Y, Inamoti N. Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distension in rabbits. *J Pharmacol Exp Ther* 2002;300:925-31.
- [8] Greenwood-Van Meerveld B, Gibson MS, Johnson AC, Venkova K, Sutkowski-Markmann D. NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig. *Pharmacol Biochem Behav* 2003;74:1005-013.

[9] Varty GB, Cohen-Williams ME, Hunter JC. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. *Behav Pharmacol* 2003;14:87-95.

[10] Kakol-Palm D, Brusberg M, Sand E, Larsson H, Martinez V, Joahnsson A, von Mentzer B, Pålhalman I, Lindström E. Role of tachykinin NK1 and NK2 receptors in colonic sensitivity and stress-induced defecation in gerbils. *Eu J Pharmacol* 2008; 582:123-31.

[11] Fong TM, Yu H, Strader CD,. Molecular basis for species selectivity of the neurokinin-1 receptor antagonist CP-96,345. *J Biol Chem* 1992;267:25668-71.

[12] Sachais BS, Snider RM, Lowe JA, Krause JE. Molecular basis for species selectivity of the substance P antagonist CP-96,345. *J Biol Chem* 1993;268:2319-23.

[13] Pradier L, Habert-Ortoli E, Le Guern J, Loquet I, Bock M-D, et al. Molecular determinants of species selectivity of neurokinin type 1 receptor antagonists. *Mol Pharmacol* 1995;45:314-21.

[14] Sachais BS, Krause JE. Both extracellular and transmembrane residues contribute to the species selectivity of the neurokinin-1 receptor antagonist WIN51708. *Mol Pharmacol* 1994;46:122-128.

[15] Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, Twissell DJ, Ward P. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad spectrum anti-emetic activity. *Regul Pept* 1996;27:45-53.

[16] Meini S, Bellucci F, catalane C, Cucchi P, Pattacchini R, Rotondaro L, Altamura M, Giuliani S, Giolitti A, Maggi C. Mutagenesis at the human tachykinin NK₂ receptor to define the binding site of a novel class of antagonists. *Eur J Pharmacol* 2004;488:61-9.

[17] Cialdai C, Tramontana M, patacchini R, Lecci A, Catalani C, Catalioto RM, Meini S, valenti C, Altamura M, Giuliani S, Maggi CA. Men 155596, a novel nonpeptide tachykinin NK2 receptor antagonist. Eur J Pharmacol 2006;549:140-8.

[18] Catlioto RM, Criscuoli RM, Cucchi P, Giachetti A, Gianotti D, Giuliani S, Lecci A, Lippi A, Patacchini R, Quartara L, Renzetti AR, Tramontana M, Arcamone F, Maggi CA..MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist. Br J Pharmacol 1998;23:81-91.

[19] Advenier C, Rouissi N, Nguyen QT, Emonds-Alt X, Breliere JC, Neliat G, *et al.* Neurokinin A (NK2) receptor revisited with SR 48968, a potent non-peptide antagonist. Biochem Biophys Res Commun 1992;184:1418-24.

[20] Chung F-Z, Wu L-H, Tian Y, Vartanian MA, Lee H, Bikker J, Humblet C, Pritchard MC, Raphy J, Suman-Chauhan N, Howell DC, Lalwani ND, Oxender DL. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin-3 receptor. Mol Pharm 1995;48:711-16.

[21] Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD, Giardina GA, Hay DWP. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther 1997;281:1303-11.

[22] Wu, Lan-Hsin, Vartainen, Marsha A, Oxender, Dale L, Chung, Fu-Zon. Identification of Methionine134 and Alanine146 in the second transmembrane segment of the human tachykinin NK3 receptor as residues involved in species-selective binding to SR48968. Biochem Biophys Res Com 1994;198:961-66.

[23] Bernstein PR, Aharony D, Alberts JS, Andisik D, Barthlow HG, Bialecki R, Davenport t, Dedinas RF, Dembofsky BT, Koether G. Discovery of novel active dual NK1/NK2 antagonists. Bioorg Med Chem Lett 2001;11:2769-73.

[24] Hale JJ, Mills SG, MacCoss M, Finke PE, Cascieri MA, Sadowski S, Ber E, Chicchi GG, Kurtz M, Metzger J et al. Structural optimization affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenoxy)-3(S)-(4-fluorophenyl)-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long acting morpholine acetal human NK-1 receptor antagonist. *J Med Chem* 1998;41:4607-14.

[25] Peyronel AT, Moutonier C, Garret C, Synthesis of RP-67,580, a new potent non-peptide substance P antagonist. *Bioorg Med Chem Lett* 1992;2:37-40.

[26] McLean S, Ganong A, Seymore PA, Snider RM, Desai MC, Rosen T, Bryce DK, Longo KP, Reynolds LS, Robinson G. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. *J Pharmacol Exp Ther* 1993;267:472-79.

[27] Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME. Nonpeptide tachykinin receptor antagonist: I. Pharmacological and Pharmacokinetic characterization of SB 223412, a novel potent and selective neurokinin-3 antagonist. *J Pharmacol Exp Ther* 1997;281:1303-11.

[28] Giardina GA, Raveglia LF, Grugni M, sarau HM, Farina C, Medhurst AD, Graziani D, Schmidt DB, Rigolio R, Luttman M, cavaguera S, Foley JJ, Vecchietti V, Hay DW. Discovery of a novel class of selective non-peptide antagonist for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl-3-hydroxy-2-phenylquinoline-4-carboxamid(SB 223412). *J Med Chem* 1999;42:1053-65.

[29] Edmonds-Alt X, Bichon D, Dueoux JP, Heaulme M, Miloux B, Ponelet M, Proietto V, van Broeck D, Vilain P, Neliat G, Soubrie P, LeFur G, Brelière JC. SR 142801 the first potent non-peptide antagonist of the tachykinin NK3 receptor. *Life Sci* 1995;56:PL27-32.

[30] Nguyen-LE X, Nguyen QT, Gobeil F, Pheng LH, Edmonds-Alt X, Brelière JC, Regoli D. Pharmacological characterization of SR 142801: a new non-peptide antagonist of the neurokinin NK-3 receptor. *Pharmacology* 1996;52:283-91.

[31] Sundqvist M, Kristensson E, Adolfsson R, Leffler A, Ahlstedt, I, Engberg S, Drmota T, Sigfridsson K, Jussila R, de Verdier J, Novén A, Johansson A, Pålman I, von Mentzer B, Lindström E. Senktide-induce gerbil foot tap behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists. *Eu J Pharmcaol* 2007; 577: 78-86.

[32] Larkin, M.A., Blackshields, G., Brown, N.P., Chenna, R., McGettigan, P.A., McWilliam, H., Valentin, F., Wallace, I.M., Wilm, A., Lopez, R., Thompson, J.D., Gibson, T.J., Higgins, D.G. (2007) Clustal W and Clustal X version 2.0. *Bioinformatics* 2007;23:2947-48

[33] Teller DC, Okada T, Behnke CA, Palczewski K, Stenkamp R, Stenkamp RE, Advances in determination of a high-resolution three dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). *Biochemistry* 2001;40:7761-72.

[34] Cheng Y, Prusoff WH. Relationship between the inhibitiuon constant (K_i) and the concentration of inhibitor, which cause 50 percent inhibition (IC_{50}) of an enzymatic reaction. *Biochem Pharmacol* 1973;22:3099-108.

[35] De la Puente-Redondo V, Tingley FD 3rd, Scheider RP, Hickman MA. The neurokinin-1 antagonist activity of marmopitant, an antiemetic drug for dogs, in a gerbil model. *J Vet Pharmacol Ther* 2007;30:281-287.

[36] Rupniak NMJ, Carlson EJ, Shepherd S, Bentley G, Williams AR, Hill A, Swain C, Mills SG, Di Salvo J, Kilburn R, Cascieri MA, Kurtz MM, Tsao K-L, Gould SL, Chicchi GG. Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608. *Neuropharmacol* 2003; 45:231-241.

[37] Poulsen A, Björholm B, gundetofte K, Pogozeva ID, Liljefors T. Pharmacophore and receptor models for neurokinin receptors. *J Computer-Aided Mol Design* 2003;17:765-83.

[38] Sarau HM, Griswold DE, Bush B, Potts W, sandhu P, Lundberg D, Foley JJ, Schmidt DB, Webb EF, martin LD, Legos JJ, Whitmore RG, barone FC, Medhurst AD, Luttmann MA, Giardina GA, Hay DW. Nonpeptide tachykinin receptor antagonist. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK3 receptor antagonist. *J Pharmacol Exp Ther* 2000; 295:373-81.

[39] Malherbe P, Bissantz C, Marcuz A, Kratzeisen C, Zenner MT, Wettstein JG, Ratni H, Riemer C, Spooren W. Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin NK3 receptor transmembrane domains. *Mol. Pharmacol* 2008;73:1736-50.

[40] Salomé N, Stemmelin J, Cohen C, Griebel G. Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. *Pharmacol Biochem Behav* 2006;83:533-539.

[41] Ahlstedt I, Engberg S, Smith J, Perrey C, Moody A, Morten J, Lagerström-Fermér M, Drmota T, von Mentzer B, Pählman I, Lindström E. Occurrence and pharmacological characterization of four human tachykinin NK2 receptor variants. *Biochem Pharmacol* 2008;76:476-481.

Table 1. Accession numbers for the cloned NKR from human, rat, gerbil and dog and the accession numbers for NKR from mouse and guinea pig used in the alignments of NK receptors.

Receptor	Species	Acc number
NK ₁	human	NM_001058
NK ₂	human	AY322545
NK ₃	human	M89473
NK ₁	rat	J05097
NK ₂	rat	M31838
NK ₃	rat	NM_017053
NK ₁	gerbil	AJ884917
NK ₂	gerbil	AJ884918
NK ₃	gerbil	AM157740
NK ₁	dog	AJ884915
NK ₂	dog	AJ884916
NK ₃	dog	AM423140
NK ₁	mouse	NM_009313
NK ₂	mouse	NM_009314
NK ₃	mouse	NM_021382
NK ₁	guinea pig	P30547
NK ₂	guinea pig	Q64077
NK ₃	guinea pig	P30098

Table 2. Primers used in the 3'RACE and in the 5'RACE of NK₁R, NK₂R and NK₃R.

receptor	species	primer sequence	reaction	original sequence
NK1	dog	CCCTCGTAGTCGCCGGCGCTGATAAAG	5'RACE	dog S75109
NK1	dog	CCCTTTATCAGCGCCGGCGACTACGAG	3'RACE	dog S75109
NK2	dog	CACTGTAGGCGACGATCATCACCAAGAG	5'RACE	dog S75024
NK2	dog	TCTCTTGGTGATGATCGTCGCCTACAGTG	3'RACE	dogS75024
NK3	dog	GGGACCTTCTGGCCATTGCACATAACA	5'RACE	dog S75029
NK3	dog	CATGCCAGGCCGTACCCTTTGTTATGTGC	3'RACE	dog S75029
NK2	gerbil	GGAAAGCAAGCCGGAATCCAGAGCG	5'RACE	rat and mouse alignment
NK2	gerbil	GGCTGCCCTACCACCTCTACTTCATCCT	3'RACE	gerbil

Table 3. Potency of selective NK receptor antagonists and the pan-NKR antagonist ZD6021 on substance P (NK₁R), NKA (NK₂R) and Pro7NKB (NK₃R) evoked increases in intracellular Ca²⁺ mobilization. Data are expressed as pK_B values ± SEM, n = 3-5.

Compound	Human	Dog	Gerbil	Rat
NK₁R				
ZD6021	8.6 ± 0.4	9.5 ± 0.2	9.0 ± 0.2	<6
RP67580	7.1 ± 0.4	7.1 ± 0.6	6.5 ± 0.2	7.3 ± 0.4
CP99,994	8.7 ± 0.2	9.8 ± 0.3	8.9 ± 0.3	5.9 ± 0.2
Aprepitant	8.7 ± 0.2	9.2 ± 0.1	8.8 ± 0.2	7.3 ± 0.1
NK₂R				
ZD6021	8.3 ± 0.4	8.4 ± 0.2	8.4 ± 0.3	8.1 ± 0.1
Saredutant	9.1	9.4 ± 0.1	9.3 ± 0.2	9.4 ± 0.1
NK₃R				
ZD6021	7.9 ± 0.3	7.8 ± 0.1	7.9 ± 0.1	6.7 ± 0.2
Talnetant	8.6 ± 0.3	8.4 ± 0.2	8.4 ± 0.1	7.4 ± 0.2
Osanetant	8.4 ± 0.5	8.2 ± 0.2	8.0 ± 0.2	7.4 ± 0.3

Legends to Figures

Figure 1. **(A)**: Sequence alignments of NK₁Rs from gerbil, human, dog, rat, mouse and guinea pig. TM regions are under lined, sequence differences indicated by gray shading and amino acids predicted to be important for antagonist binding are boxed. **(B)**: Dose-dependent inhibitory effect of the selective NK₁R antagonist aprepitant on SP-evoked mobilization of intracellular Ca²⁺ in cells expressing the NK₁R from various species. Representative curves from each animal from three experiments done, are shown, all performed in the same experiment (see Table 3). **(C)**: Chemical sequences of amino acids interacting in the NK₁R binding site in the presence of aprepitant. Bold numbers on AA indicate change as compared to the human AA. AA marked in bold show a TM region species difference.

Figure 2. **(A)**: Sequence alignments of NK₂Rs from gerbil, human, dog, rat, mouse and guinea pig. Tm regions are under lined, sequence differences indicated by gray shading and amino acids predicted to be important for antagonist binding are boxed. **(B)**: Representative curve illustrating the dose-dependent inhibitory effect of the selective NK₂ receptor antagonist saredutant on NKA-evoked mobilization of intracellular Ca²⁺ in cells expressing the NK₂ receptor from various species. Representative curves from each animal from three experiments done, are shown, all performed in the same experiment (see Table 3). **(C)**: Chemical sequences of amino acids interacting in the NK₂R binding site in the presence of saredutant. Bold numbers on AA indicate change as compared to the human AA. AA marked in bold show a TM region species difference.

Figure 3. (A): Sequence alignments of NK₃Rs from gerbil, human, dog, rat, mouse and guinea pig. Tm regions are under lined, sequence differences indicated by gray shading and amino acids predicted to be important for antagonist binding are boxed. (B): Representative curve illustrating the dose-dependent inhibitory effect of the selective NK₃R antagonist talnetant on NKB-evoked mobilization of intracellular Ca²⁺ in cells expressing the NK₃R from various species. Representative curves from each animal from three experiments done, are shown, all performed in the same experiment (See Table 3). (C): Chemical sequences of amino acids interacting in the NK₃R binding site in the presence of talnetant. Bold numbers on AA indicate change as compared to the human AA. AA marked in bold show a TM region species difference.

Fig 1A

1	MDNVLPQSDSLFPNISTNSSES	SNQFVQPAWQIVLWAAAYTVIVVTSVVGNNVVMWIIIAHKRMRTVTNYF	gerbil NK1r
1	MDNVLPQSDSLFPNISTNTSE	SNQFVQPAWQIVLWAAAYTVIVVTSVVGNNVVMWIIIAHKRMRTVTNYF	human NK1r
1	MDNVLPQSDSLFPNISTNTSE	SNQFVQPAWQIVLWAAAYTVIVVTSVVGNNVVMWIIIAHKRMRTVTNYF	dog NK1r
1	MDNVLPQSDSLFPNISTNTSE	SNQFVQPAWQIVLWAAAYTVIVVTSVVGNNVVMWIIIAHKRMRTVTNYF	rat NK1r
1	MDNVLPQSDSLFPNISTNTSE	SNQFVQPAWQIVLWAAAYTVIVVTSVVGNNVVMWIIIAHKRMRTVTNYF	mouse NK1r
1	MDNVLPQSDSLFPNISTNTSE	SNQFVQPAWQIVLWAAAYTVIVVTSVVGNNVVMWIIIAHKRMRTVTNYF	guinea pig NK1r
	TM1		
71	LVNLAFAEASMAAFNTV	VNFTYAVHNEWYYGLFYCKFHNFPIAAVFASIYSMTAVAFDRYMAIIHPLOP	gerbil NK1r
71	LVNLAFAEASMAAFNTV	VNFTYAVHNEWYYGLFYCKFHNFPIAAVFASIYSMTAVAFDRYMAIIHPLOP	human NK1r
71	LVNLAFAEASMAAFNTV	VNFTYAVHNEWYYGLFYCKFHNFPIAAVFASIYSMTAVAFDRYMAIIHPLOP	dog NK1r
71	LVNLAFAEASMAAFNTV	VNFTYAVHNEWYYGLFYCKFHNFPIAAVFASIYSMTAVAFDRYMAIIHPLOP	rat NK1r
71	LVNLAFAEASMAAFNTV	VNFTYAVHNEWYYGLFYCKFHNFPIAAVFASIYSMTAVAFDRYMAIIHPLOP	mouse NK1r
71	LVNLAFAEASMAAFNTV	VNFTYAVHNEWYYGLFYCKFHNFPIAAVFASIYSMTAVAFDRYMAIIHPLOP	guinea pig NK1r
	TM2	TM3	
141	RLSATATKVVIFVINVL	LALLAFPGGYSTTETMPSRVVCMIWEPHFNRTYEKAYHICVTVLYFLPLL	gerbil NK1r
141	RLSATATKVVIFVINVL	LALLAFPGGYSTTETMPSRVVCMIWEPHFNRTYEKAYHICVTVLYFLPLL	human NK1r
141	RLSATATKVVIFVINVL	LALLAFPGGYSTTETMPSRVVCMIWEPHFNRTYEKAYHICVTVLYFLPLL	dog NK1r
141	RLSATATKVVIFVINVL	LALLAFPGGYSTTETMPSRVVCMIWEPHFNRTYEKAYHICVTVLYFLPLL	rat NK1r
141	RLSATATKVVIFVINVL	LALLAFPGGYSTTETMPSRVVCMIWEPHFNRTYEKAYHICVTVLYFLPLL	mouse NK1r
141	RLSATATKVVIFVINVL	LALLAFPGGYSTTETMPSRVVCMIWEPHFNRTYEKAYHICVTVLYFLPLL	guinea pig NK1r
	TM4		
211	MIGYAYTVVGI	TLWASEIPGDSSDRYHEQVSARKKVVQMIVVVCTFAICWLPFHIFELL	gerbil NK1r
211	MIGYAYTVVGI	TLWASEIPGDSSDRYHEQVSARKKVVQMIVVVCTFAICWLPFHIFELL	human NK1r
211	MIGYAYTVVGI	TLWASEIPGDSSDRYHEQVSARKKVVQMIVVVCTFAICWLPFHIFELL	dog NK1r
211	MIGYAYTVVGI	TLWASEIPGDSSDRYHEQVSARKKVVQMIVVVCTFAICWLPFHIFELL	rat NK1r
211	MIGYAYTVVGI	TLWASEIPGDSSDRYHEQVSARKKVVQMIVVVCTFAICWLPFHIFELL	mouse NK1r
211	MIGYAYTVVGI	TLWASEIPGDSSDRYHEQVSARKKVVQMIVVVCTFAICWLPFHIFELL	guinea pig NK1r
	TM5	TM6	
281	KFIQQVYLA	IMWLAMSSMTYNPIIYCCCLNDRFRLGFKHAFFCCPFISAGDYE	gerbil NK1r
281	KFIQQVYLA	IMWLAMSSMTYNPIIYCCCLNDRFRLGFKHAFFCCPFISAGDYE	human NK1r
281	KFIQQVYLA	IMWLAMSSMTYNPIIYCCCLNDRFRLGFKHAFFCCPFISAGDYE	dog NK1r
281	KFIQQVYLA	IMWLAMSSMTYNPIIYCCCLNDRFRLGFKHAFFCCPFISAGDYE	rat NK1r
281	KFIQQVYLA	IMWLAMSSMTYNPIIYCCCLNDRFRLGFKHAFFCCPFISAGDYE	mouse NK1r
281	KFIQQVYLA	IMWLAMSSMTYNPIIYCCCLNDRFRLGFKHAFFCCPFISAGDYE	guinea pig NK1r
	TM7		
351	VSRLTETISTVVG	AHEEEDGPKATPSSDLT	gerbil NK1r
351	VSRLTETISTVVG	AHEEEDGPKATPSSDLT	human NK1r
351	VSRLTETISTVVG	AHEEEDGPKATPSSDLT	dog NK1r
351	VSRLTETISTVVG	AHEEEDGPKATPSSDLT	rat NK1r
351	VSRLTETISTVVG	AHEEEDGPKATPSSDLT	mouse NK1r
351	VSRLTETISTVVG	AHEEEDGPKATPSSDLT	guinea pig NK1r

Fig 1B

Fig 1C

Species difference in NK1R.

Aprepitant

Fig 2A

1	MGAYAIIVTDNIIISGLQNTTGVTAFSMPAQWQLALNATAYLALVLVAVTGNATVIWIIIAHERMRTVTNY	gerbil NK2r
2	1	
3	1	
4	1	
5	1	
6	1	
7	1	
8	1	
9	1	
10	1	
11	1	
12	1	
13	1	
14	1	
15	1	
16	1	
17	1	
18	1	
19	1	
20	1	
21	1	
22	1	
23	1	
24	1	
25	1	
26	1	
27	1	
28	1	
29	1	
30	1	
31	1	
32	1	
33	1	
34	1	
35	1	
36	1	
37	1	
38	1	
39	1	
40	1	
41	1	
42	1	
43	1	
44	1	
45	1	
46	1	
47	1	
48	1	
49	1	
50	1	
51	1	
52	1	
53	1	
54	1	
55	1	
56	1	
57	1	
58	1	
59	1	
60	1	
61	1	
62	1	
63	1	
64	1	
65	1	

Fig 2B

Fig 2C

Species difference in NK2R

202

H Ile

G Phe

R Phe

D Ile

267

H Leu

G Leu

R Leu

D Phe

205

H Ile

G Val

R Ile

D Ile

SR48968

Fig 3A

1	MASVPTAESESWTDGAAGVGTQVGNLSSALGV-----TEWELAQ--AGNFSSALG---VPVTSPTPS	gerbil NK3r
1	MATLPAAEET--WIDGGGGVGDADAVNLTAIAAGAATGAVETGHLQLLDQAGNELSSSPALGLFVASPAPS	human NK3r
1	MGSLLPAAET--WIDRAGPAGAGGGNLSAALAAGAA--AAGAEMQLLLGRAGNLSASP-----PAASAAPA	dog NK3r
1	MASVPTGEN--WTDGTVEVGTHTGNLSSALGV-----TEWLALQ--AGNFSSALG---LPATTQAPS	rat NK3r
1	MASVPTGEN--WTDGTAGVGSHTGNLSSALGI-----TEWLALQ--AGNFSSALG---LPVTSQAPS	mouse NK3r
1	MASPAENLS--AWPGHGWPPPAALNLTSSAP-----TASPS-----PAPSNTPS	guinea pig NK3r
58	QARANLTNQFVQPSWRIALWSLAYGLVVAVAVFGNLIVIVIILAHKRMRTVTNYFLVNLAFLSDASMAAFN	gerbil NK3r
69	QPRANLTNQFVQPSWRIALWSLAYGLVVAVAVFGNLIVIVIILAHKRMRTVTNYFLVNLAFLSDASMAAFN	human NK3r
63	QPRANLTNQFVQPSWRIALWSLAYGLVVAVAVFGNLIVIVIILAHKRMRTVTNYFLVNLAFLSDASMAAFN	dog NK3r
56	QVRANLTNQFVQPSWRIALWSLAYGLVVAVAVFGNLIVIVIILAHKRMRTVTNYFLVNLAFLSDASMAAFN	rat NK3r
56	QVRANLTNQFVQPSWRIALWSLAYGLVVAVAVFGNLIVIVIILAHKRMRTVTNYFLVNLAFLSDASMAAFN	mouse NK3r
45	-PRPGPAHFFLQPPMRVALWSLAYGLVVAVAVFGNLIVIVIILAHKRMRTVTNLSFLVNLAFLADAMAAFN	guinea pig NK3r
TM1 TM2		
128	TLVNFIALHSEWYFGANYCRFQNEFFPITAVFASIYSMTAIAVDRYMAIIDPLKPRLSATATKIVIGSIW	gerbil NK3r
139	TLVNFIALHSEWYFGANYCRFQNEFFPITAVFASIYSMTAIAVDRYMAIIDPLKPRLSATATKIVIGSIW	human NK3r
133	TLVNFIALHSEWYFGANYCRFQNEFFPITAVFASIYSMTAIAVDRYMAIIDPLKPRLSATATKIVIGSIW	dog NK3r
126	TLVNFIALHSEWYFGANYCRFQNEFFPITAVFASIYSMTAIAVDRYMAIIDPLKPRLSATATKIVIGSIW	rat NK3r
126	TLVNFIALHSEWYFGANYCRFQNEFFPITAVFASIYSMTAIAVDRYMAIIDPLKPRLSATATKIVIGSIW	mouse NK3r
114	ALVNFIALHSEWYFGANYCRFQNEFFPITAVFASIYSMTAIAVDRYMAIIDPLKPRLSATATKIVIGSIW	guinea pig NK3r
TM3		
198	ILAFLLAFQCLYSKIKVMPGRTLCTVQWPEGPKQHFTYHIIVILVYCFPLLIMQVITYTIVGITLWGGE	gerbil NK3r
209	ILAFLLAFQCLYSKIKVMPGRTLCTVQWPEGPKQHFTYHIIVILVYCFPLLIMQVITYTIVGITLWGGE	human NK3r
203	ILAFLLAFQCLYSKIKVMPGRTLCTVQWPEGPKQHFTYHIIVILVYCFPLLIMQVITYTIVGITLWGGE	dog NK3r
196	ILAFLLAFQCLYSKIKVMPGRTLCTVQWPEGPKQHFTYHIIVILVYCFPLLIMQVITYTIVGITLWGGE	rat NK3r
196	ILAFLLAFQCLYSKIKVMPGRTLCTVQWPEGPKQHFTYHIIVILVYCFPLLIMQVITYTIVGITLWGGE	mouse NK3r
184	ILAFLLAFQCLYSKIKVMPGRTLCTVQWPEGPKQHFTYHIIVILVYCFPLLIMQVITYTIVGITLWGGE	guinea pig NK3r
TM4 TM5		
268	IPGDTCDKYHEQLKAKRKVVQMIIIVVTFIAICWLPYHIFILTAIYQQLNRNKYIQQVYLASFWMSS	gerbil NK3r
279	IPGDTCDKYHEQLKAKRKVVQMIIIVVTFIAICWLPYHIFILTAIYQQLNRNKYIQQVYLASFWMSS	human NK3r
273	IPGDTCDKYHEQLKAKRKVVQMIIIVVTFIAICWLPYHIFILTAIYQQLNRNKYIQQVYLASFWMSS	dog NK3r
266	IPGDTCDKYHEQLKAKRKVVQMIIIVVTFIAICWLPYHIFILTAIYQQLNRNKYIQQVYLASFWMSS	rat NK3r
266	IPGDTCDKYHEQLKAKRKVVQMIIIVVTFIAICWLPYHIFILTAIYQQLNRNKYIQQVYLASFWMSS	mouse NK3r
254	IPGDTCDKYHEQLKAKRKVVQMIIIVVTFIAICWLPYHIFILTAIYQQLNRNKYIQQVYLASFWMSS	guinea pig NK3r
TM6		
338	TMYNPIIYCCLNKRFRAFGRFRCPCFIQVSSYDELELKTTRFHPTRQSSLYTVSRMESVTVLFDPNNG	gerbil NK3r
349	TMYNPIIYCCLNKRFRAFGRFRCPCFIQVSSYDELELKTTRFHPTRQSSLYTVSRMESVTVLFDPNNG	human NK3r
343	TMYNPIIYCCLNKRFRAFGRFRCPCFIQVSSYDELELKTTRFHPTRQSSLYTVSRMESVTVLFDPNNG	dog NK3r
336	TMYNPIIYCCLNKRFRAFGRFRCPCFIQVSSYDELELKTTRFHPTRQSSLYTVSRMESVTVLFDPNNG	rat NK3r
336	TMYNPIIYCCLNKRFRAFGRFRCPCFIQVSSYDELELKTTRFHPTRQSSLYTVSRMESVTVLFDPNNG	mouse NK3r
324	TMYNPIIYCCLNKRFRAFGRFRCPCFIQVSSYDELELKTTRFHPTRQSSLYTVSRMESVTVLFDPNNG	guinea pig NK3r
TM7		
408	DPAKSSRKRAVPRDPSANGCSHREKSASTTSSFISSPYTSVDEYS	gerbil NK3r
419	DTTRSSRKRAVPRDPSANGCSHREKSASTTSSFISSPYTSVDEYS	human NK3r
413	DNTKSSRKRAVPRDPSANGCSHREKSASTTSSFISSPYTSVDEYS	dog NK3r
406	DPTKSSRKRAVPRDPSANGCSHREKSASTTSSFISSPYTSVDEYS	rat NK3r
406	DPAKSSRKRAVPRDPSANGCSHREKSASTTSSFISSPYTSVDEYS	mouse NK3r
394	DSARSSHQKRGTRDPSANGCSHREKSASTTSSFISSPYTSVDEYS	guinea pig NK3r

Fig 3B

Fig 3C

Species difference in NK3R

Talnetant

Experiments with Neurokinin receptors (NKR) demonstrate that not only human, but also dog and gerbil NKR displays similar antagonist pharmacology while rat diverges significantly with respect to NK₁R and NK₃R.

Potencies of selective NKR antagonists and of the pan-NKR antagonist ZD6021.

Compound	Human	Dog	Gerbil	Rat
NK₁R				
ZD6021	8.6 ± 0.4	9.5 ± 0.2	9.0 ± 0.2	<6
RP67580	7.1 ± 0.4	7.1 ± 0.6	6.5 ± 0.2	7.3 ± 0.4
CP99,994	8.7 ± 0.2	9.8 ± 0.3	8.9 ± 0.3	5.9 ± 0.2
Aprepitant	8.7 ± 0.2	9.2 ± 0.1	8.8 ± 0.2	7.3 ± 0.1
NK₂R				
ZD6021	8.3 ± 0.4	8.4 ± 0.2	8.4 ± 0.3	8.1 ± 0.1
Saredutant	9.1	9.4 ± 0.1	9.3 ± 0.2	9.4 ± 0.1
NK₃R				
ZD6021	7.9 ± 0.3	7.8 ± 0.1	7.9 ± 0.1	6.7 ± 0.2
Talnetant	8.6 ± 0.3	8.4 ± 0.2	8.4 ± 0.1	7.4 ± 0.2
Osanetant	8.4 ± 0.5	8.2 ± 0.2	8.0 ± 0.2	7.4 ± 0.3